Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV

The impact of imatinib dose on response rates and survival in older patients with chronic myeloid leukemia in chronic phase has not been studied well. We analyzed data from the German CML-Study IV, a randomized five-arm treatment optimization study in newly diagnosed BCR-ABL-positive chronic myeloid...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Proetel, Ulrike, Pletsch, Nadine, Lauseker, Michael, Müller, Martin C., Hanfstein, Benjamin, Krause, Stefan W., Kalmanti, Lida, Schreiber, Annette, Heim, Dominik, Baerlocher, Gabriela M., Hofmann, Wolf-Karsten, Lange, Elisabeth, Einsele, Hermann, Wernli, Martin, Kremers, Stephan, Schlag, Rudolf, Müller, Lothar, Hänel, Mathias, Link, Hartmut, Hertenstein, Bernd, Pfirrmann, Markus, Hochhaus, Andreas, Hasford, Joerg, Hehlmann, Rüdiger, Saußele, Susanne
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Springer Berlin Heidelberg 2014
Θέματα:
Original Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4050299/
https://ncbi.nlm.nih.gov/pubmed/24658964
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00277-014-2041-0
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια